Chronic Hepatitis C Prevalence, Genotype Distribution and Treatment Responses at Marmara University Pendik Training and Research Hospital Between 2014-2018

Öz

Hepatitis C is a serious disease that is common in the world and may cause mortality. In this study, we aimed to determine frequency of HCV antibody, genotype distribution and treatment successes of the patients who were received treatment for chronic viral hepatitis C (HCV) in Marmara University Pendik Training and Research Hospital. Between January 2014 and December 2018, serum samples with HCV antibody requests were screened. HCV RNA test results and genotype distribution of reactive samples were evaluated. Permanent virologic response rates of patients receiving treatment are shown. HCV antibody was requested in 100,100 serum samples from 76,413 patients and was found positive in 1,808 (2,36 %) patients. HCV RNA test was performed in 1286 (71 %) reactive samples. HCV RNA was positive in 291 (23 %) of 1286 HCV antibody positive samples. Of those HCV RNA positive patients, 44 % were given treatment for HCV in the hospital. The most common genotype was 1b. Sustained virologic response at 24 weeks after the end of treatment was achieved in 87 % of patients. Although the virological success rates with antiviral treatment are satisfactory, the number of patients who still need to be diagnosed and eligible for treatment is quite high.

Anahtar Kelimeler

• anti-Hepatitis C virus antibodies
• chronic hepatitis C
• genotype
• prevalance

Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi’nde 2014-2018 Yılları Arasındaki Kronik Hepatit C Prevalansı, Genotip Dağılımı ve Tedavi Yanıtları

Öz

Hepatit C dünyada yaygın olarak görülen ve mortaliteye neden olabilen ciddi bir hastalıktır. Bu çalışmada Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi’ne başvuran hastalarda anti-HCV seropozitiflik sıklığının ve kronik viral hepatit C (HCV) tanısı konarak tedavi verilen hastaların genotip dağılımları ile tedavi başarılarının değerlendirilmesi amaçlanmıştır. Çalışmada retrospektif olarak Ocak 2014-Aralık 2018 tarihleri arasında anti-HCV istemi yapılan serum örnekleri taranmıştır. Reaktif bulunan örneklerin HCV RNA pozitiflikleri ile genotip dağılımları ve kronik HCV tanısı ile tedavi verilen hastaların kalıcı viral yanıt başarı oranları değerlendirilmiştir. Total 76,413 hastadan 100,100 serum örneğinde anti-HCV istemi yapılmış ve 1,808 (% 2,36) hastada pozitif bulunmuştur. Bu hastaların 1,286’sında (% 71) HCV RNA bakılmış ve 291 (% 23) hastada pozitif saptanmıştır. HCV RNA tespit edilen hastalarda 129’una (% 44) hastanemizde kronik HCV tanısı ile tedavi verilmiştir. En sık genotip 1b saptanmış olup, tedavi sonrası 24’üncü haftada kalıcı viral yanıt hastaların % 87’sinde elde edilmiştir. Sonuç olarak antiviral tedavi ile virolojik başarı oranları yüz güldürücü olsa da halen tanı ve tedavi alması gereken ancak tespit edilemeyen hasta sayısı da oldukça yüksektir.

Anahtar Kelimeler

• anti-Hepatit C virüs antikorları
• genotip
• kronik hepatit C
• prevalans

Kaynakça

1. Altuglu I, Tanyeri S, Zeytinoglu A, Altintoprak AE. HBsAg, Anti-HCV and Anti-HIV seroprevalance among drug users: a retrospective assessment. Noro Psikiyatr Ars. 2019;56(3):186-90. https://doi.org/10.29399/npa.23505
2. Aygen B, Demirturk N, Turker N, Asan A, Eraksoy H, Gurbuz Y, Inan D ve ark. Kronik Hepatit C virusu infeksiyonunun yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği viral hepatit çalışma grubu uzlaşı raporu-2017 güncellemesi. Klimik Derg. 2017;30(Özel Sayı 1):2-36.
3. Cinar Tanriverdi E, Ozkurt Z, Goktug Kadioglu B, et al. Seroprevalence of hepatitis B, hepatitis C, and HIV in pregnant women from Eastern Turkey. Turk J Gastroenterol. 2019;30(3):260-5. https://doi.org/10.5152/tjg.2018.17634
4. Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). J Viral Hepat. 2014;21(Suppl 1):1-4. https://doi.org/10.1111/jvh.12253
5. European Association for the Study of the Liver (EASL), EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461- 511. https://doi.org/10.1016/j.jhep.2018.03.026
6. European Union HCVC. Hepatitis C virüs prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325-36. https://doi.org/10.1016/S2468-1253(17)30045-6
7. Ghany MG, Morgan TR, Panel A-IHCG. Hepatitis C Guidance 2019 Update: American association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71(2):686-721. https://doi.org/10.1002/hep.31060
8. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(Suppl 1):S45-57. https://doi.org/10.1016/j.jhep.2014.07.027

9. Gürbüz Y TN, Tütünce EE, Tekin S, Aygen B, Demirtürk N, Kınıklı S ve ark. Evaluation of dual therapy in real life setting in treatment-naive Turkish patients with HCV infection: a multicenter, retrospective study. Balkan Med J. 2016;33(1):18-26. https://doi.org/10.5152/balkanmedj.2015.15859
10. Halk Sağlığı Genel Müdürlüğü. Türkiye Viral Hepatit Önleme ve Kontrol Programı 2018-2023 Ankara: Sağlık Bakanlığı [erişim 30 Ocak 2019] 2018 [Available from: https://hsgm.saglik.gov. tr/depo/birimler/Bulasici-hastaliklar-db/duyurular/Turkiye_Viral_Hepatit_Onleme_ve_ Kontrol_Programi/Turkiye_Viral_Hepatit_Onleme_ve_Kontrol_Programi_TR.pdf
11. Kose S, Adar P, Gozaydin A, Kuzucu L, Akkoclu G. hepatitis B and hepatitis C in prisons: a prevalence study. Int J Prison Health. 2019;15(2):162-7. https://doi.org/10.1108/IJPH-01-2018-0004
12. Manns MP, Buti M, Gane E, et al. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3(7):17006. https://doi.org/10.1038/nrdp.2017.6
13. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87. https://doi.org/10.1002/hep.27259
14. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virüs genotypes. World J Gastroenterol. 2016;22(34):7824-40. https://doi.org/10.3748/wjg.v22.i34.7824
15. Tosun S. Epidemiology of viral hepatitis in Turkey: a meta-analysis of all published papers. “Tabak F, Tosun S (eds). Viral hepatitis 2013, s.27-9, İstanbul, Tip Publisher. (2013).
16. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virüs infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020-6. https://doi.org/10.1016/j.cmi.2015.06.028
17. WHO. Global Hepatitis Report 2017 [Available from: https://apps.who.int/iris/bitstream/hand le/10665/255016/9789241565455-eng.pdf;jsessionid=2CCDA0EB027C189AAAFC87CC2A8C38 D6?sequence=1.
18. Yildiz SM, Candevir A, Kibar F, et al. Hepatitis B, hepatitis C, human immunodeficiency virus and syphilis frequency among blood donors: a single center study. Transfus Apher Sci. 2015;53(3): 308-14. https://doi.org/10.1016/j.transci.2015.05.022